Exosomes Archives | BioInformant

Longevity Medical Institute® Launches Advanced Intranasal Regenerative Neurological Therapy Platform

July 23, 2026 By BioInformant Team Leave a Comment

Non-invasive nose-to-brain delivery system expands treatment options for patients with neurological disorders as an alternative to intrathecal administration.

SAN JOSé DEL CABO, BAJA CALIFORNIA SUR, MEXICO, July 23, 2026 — Longevity Medical Institute^® today announced the launch of its Regenerative Neurological Therapy Program, featuring an advanced intranasal delivery platform designed to transport regenerative therapies toward the brain through the nasal cavity. The technology expands the institute’s comprehensive neurological program by offering patients a non-invasive alternative to intrathecal administration for selected neurological conditions.
[Read more…]

Exosomes: Company Spotlights from “A” to “Z”

July 9, 2026 By Cade Hildreth, Founder & President 10 Comments

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.

With at least 26,805 scientific articles published about exosomes and 301 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. The term “exosomes” has become an increasingly common Search Term on Google over the past 10 years, as shown in the graph below: [Read more…]

RoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. Customers

July 7, 2026 By BioInformant Team Leave a Comment

Distribution agreement gives U.S. customers a single-vendor source for high-quality cells, bioprocess media, and recombinant growth factors—giving cell and exosome therapy developers a single, translation-friendly source for critical raw materials

FREDERICK, MD., July 7, 2026 — RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins. Under the agreement, customers in the United States can now order Qkine’s full range of translation-friendly research use only (RUO) growth factors and cytokines directly from RoosterBio. [Read more…]

Exosomes as a New Class of Cell-Free Therapeutics and Diagnostics

July 6, 2026 By Cade Hildreth, Founder & President Leave a Comment

Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers (nm). Exosomes are formed by the invagination of the cell membrane. This invagination and subsequent budding result in the formation of early endosomes. These early endosomes then mature into late endosomes, which are also called multivesicular bodies (MVBs). Finally, these MVBs migrate and fuse with the plasma membrane to release exosomes outside the cell. [Read more…]

The Emerging Role of Exosome Therapeutics in 2026

June 21, 2026 By Cade Hildreth, Founder & President 4 Comments

Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells. [Read more…]